Pfizer/Seagen And What May Follow

Mintz is a litigation powerhouse and business accelerator serving leaders in life sciences, private equity, sustainable energy, and technology. The world’s most innovative companies trust Mintz to provide expert advice, protect and monetize their IP, negotiate deals, source financing, and solve complex legal challenges. The firm has over 600 attorneys across offices in Boston, Los Angeles, Miami, New York, Washington, DC, San Francisco, San Diego, and Toronto.

Explore Firm Details

Member Matthew Gardella was a panelist on Scrip's M&A Podcast, where he discussed the state of biopharma M&A, including the record pace of activity in 2023...

United States Corporate/Commercial Law

Member Matthew Gardella was a panelist on Scrip's M&A Podcast, where he discussed the state of biopharma M&A, including the record pace of activity in 2023 and the implications of mega deals like the Pfizer/Seagen merger.

SOURCE

Scrip M&A Podcast

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Pfizer/Seagen And What May Follow

Contributor

Corporate/Commercial Law

Contributor

United States